Home Ideas & Research Indexes Hedge Funds Portfolios My tickerspy Newswire
Enter ticker(s) QQQ: 62.91 +0.72%   SPY: 135.36 +0.13%
Quote Spy PARD NEW Message Board  
Click to close X

Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders.


Poniard Pharmaceuticals (PARD)

@ 9:33 AM
Click the portfolio to add PARD:
Close [X]
+ Add PARD to Portfolio
  
  Last Trade: $1.00 0.00 (0.00%)
  Volume: 1,000 7% of avg daily volume
       
  Avg Volume: 15,184
3-Month Chart (Larger chart w/volume)
Close [X]
1m  3m  6m  1y  2y
  Day's Range: 1.00 - 1.00
  Open: 1.00
  Previous Close: 1.00
  52-wk Range: 0.71 - 18.83
  Market Cap: 1.4M
  P/E: -0.1
  Div Yield: $0.00 (0.00%)
Indexes
None
Spy PARD

? Pro holders
? Member holders
? Items submitted
Additional PARD resources



Customize Links
To see which Pros and tickerspy members own PARD Sign up now
Latest PARD Notes & Links
View: Headlines   |   Message Board   |   Portfolio Notes  

Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board
PARD  
Linked by marketwire - January 03, 08:00AM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that the Nasdaq Hearings Panel has determined to delist the  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
PARD  
Linked by marketwire - November 07, 08:30AM from (www.marketwire.com)

SAN FRANCISCO, CA--(Marketwire - Nov 7, 2011) - Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that  more ...

Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results
PARD  
Linked by marketwire - October 28, 04:01PM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals Reports Second Quarter 2011 Financial Results
PARD  
Linked by marketwire - August 12, 04:01PM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals and ALLOZYNE Sign Definitive Merger Agreement
PARD  
Linked by marketwire - June 22, 04:26PM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals Reports First Quarter 2011 Financial Results
PARD  
Linked by marketwire - May 13, 08:30AM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals Announces It Will Seek Shareholder Approval of Reverse Stock Split at Annual Meeting
PARD  
Linked by marketwire - April 12, 05:03PM from (www.marketwire.com)
SAN FRANCISCO, CA--(Marketwire - April 12, 2011) - Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
PARD  
Linked by marketwire - March 30, 05:13PM from (www2.marketwire.com)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Volume Hunter: Diet Stocks Lift Biotech
PARD  REGN  VVUS  [MATK]  RPRX  EXEL  ARNA  DNDN  OREX  
Linked by tickerspy Newswire - September 02, 03:19PM from (www.tickerspy.com)
The biotech sector was mixed on Thursday, but isolated stories sent select players soaring on notable volume spikes. A look  more ...
Post a comment
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.
Page 1 2 3 4



Close [X]
Select the external links you'd like on the quote and portfolio pages. We recommend 5 to 6 links. Request a new resource.
Profile/Financials
Yahoo! Profile
Yahoo! Key Stats
MSN Financials

Analysts
Nasdaq Analysts
Yahoo! Estimates
Charts / TA
Clearstation
Google Charts
StockCharts

Subscription
Insiderscore
10k Wizard
CallStreet
Other
Short Interest
SEC Filings
Insiders
Fool CAPS


Request a new resource